ImmunityBio (IBRX)
ImmunityBio on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
122.9M
Short interest
settlement 2026-10-15
7.2
Days to cover
-1.7 days vs prior
60.3%
Short share of volume
2026-10-28
3,076
Fails to deliver
settlement 2026-09-30
Wed 4 Nov
Next earnings
estimated date
-$1.1M
Insider flow, 90 days
0 buys, 2 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in IBRX is 122,945,839 shares, down 2,462,353 shares over the last month. Over the last 48 readings it ranged from 44,411,919 shares (13 December 2024) to 140,326,066 shares (15 April 2026). At the reported average volume of 17.2M shares a day that is 7.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ibrx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 122,945,839 | -0.9% | 17,192,904 | 7.15 |
| 2026-09-30 | 124,092,202 | -1.1% | 13,967,506 | 8.88 |
| 2026-09-15 | 125,408,192 | -0.2% | 7,907,803 | 15.86 |
| 2026-08-31 | 125,637,933 | -1.5% | 8,506,000 | 14.77 |
| 2026-08-14 | 127,495,672 | -1.2% | 8,258,532 | 15.44 |
| 2026-07-31 | 128,997,049 | -4.0% | 8,899,967 | 14.49 |
| 2026-07-15 | 134,395,641 | +1.9% | 11,271,404 | 11.92 |
| 2026-06-30 | 131,830,884 | -2.5% | 15,222,847 | 8.66 |
| 2026-06-15 | 135,149,785 | +2.3% | 11,306,801 | 11.95 |
| 2026-05-29 | 132,143,163 | -0.5% | 17,296,647 | 7.64 |
| 2026-05-15 | 132,753,919 | -3.9% | 12,565,286 | 10.57 |
| 2026-04-30 | 138,109,255 | -1.6% | 13,031,528 | 10.60 |
| 2026-04-15 | 140,326,066 | +3.5% | 14,708,594 | 9.54 |
| 2026-03-31 | 135,542,079 | +1.0% | 28,972,268 | 4.68 |
| 2026-03-13 | 134,199,301 | +1.3% | 25,500,991 | 5.26 |
| 2026-02-27 | 132,437,647 | -1.7% | 49,358,511 | 2.68 |
| 2026-02-13 | 134,701,658 | -0.3% | 21,810,198 | 6.18 |
| 2026-01-30 | 135,160,945 | +6.4% | 80,052,550 | 1.69 |
| 2026-01-15 | 127,000,990 | +5.3% | 22,840,445 | 5.56 |
| 2025-12-31 | 120,642,502 | +10.7% | 14,590,615 | 8.27 |
| 2025-12-15 | 109,024,436 | +23.1% | 13,201,119 | 8.26 |
| 2025-11-28 | 88,553,549 | +9.2% | 10,488,647 | 8.44 |
| 2025-11-14 | 81,064,526 | +9.9% | 8,826,209 | 9.18 |
| 2025-10-31 | 73,753,432 | +1.6% | 8,683,711 | 8.49 |
| 2025-10-15 | 72,564,054 | -1.2% | 10,203,792 | 7.11 |
| 2025-09-30 | 73,427,568 | -13.2% | 9,280,695 | 7.91 |
| 2025-09-15 | 84,559,728 | +12.3% | 11,493,195 | 7.36 |
| 2025-08-29 | 75,307,294 | +0.2% | 8,196,233 | 9.19 |
| 2025-08-15 | 75,175,215 | -2.5% | 9,326,768 | 8.06 |
| 2025-07-31 | 77,068,923 | +0.1% | 8,576,100 | 8.99 |
| 2025-07-15 | 76,978,537 | +0.0% | 6,137,644 | 12.54 |
| 2025-06-30 | 76,962,373 | +6.4% | 7,176,613 | 10.72 |
| 2025-06-13 | 72,356,035 | +0.3% | 13,352,637 | 5.42 |
| 2025-05-30 | 72,119,833 | -2.2% | 8,311,715 | 8.68 |
| 2025-05-15 | 73,740,245 | +7.2% | 13,228,381 | 5.57 |
| 2025-04-30 | 68,762,287 | +2.4% | 4,736,639 | 14.52 |
| 2025-04-15 | 67,182,989 | +6.3% | 8,467,505 | 7.93 |
| 2025-03-31 | 63,183,105 | +6.1% | 6,241,352 | 10.12 |
| 2025-03-14 | 59,544,447 | -2.3% | 5,279,191 | 11.28 |
| 2025-02-28 | 60,930,572 | +7.0% | 7,589,476 | 8.03 |
| 2025-02-14 | 56,962,454 | +1.9% | 4,167,831 | 13.67 |
| 2025-01-31 | 55,923,123 | +2.5% | 8,255,797 | 6.77 |
| 2025-01-15 | 54,539,713 | +9.1% | 4,862,357 | 11.22 |
| 2024-12-31 | 50,005,639 | +12.6% | 6,280,540 | 7.96 |
| 2024-12-13 | 44,411,919 | -10.8% | 7,045,717 | 6.30 |
| 2024-11-29 | 49,778,598 | -4.4% | 3,334,404 | 14.93 |
| 2024-11-15 | 52,052,392 | -1.3% | 5,686,718 | 9.15 |
| 2024-10-31 | 52,749,830 | +2.3% | 12,530,805 | 4.21 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of IBRX volume is 60.3%, up 0.2 points over the last five sessions. Over the last 30 readings it ranged from 33.4% (22 September 2026) to 68.2% (21 September 2026). The latest reading is 2.8 points above the 30-session average of 57.4%, on 3.5M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 2.1M | 3.5M | 60.3% | 25,097 |
| 2026-10-27 | 3.2M | 5.5M | 58.4% | 32,360 |
| 2026-10-26 | 3.8M | 6.3M | 61.0% | 38,069 |
| 2026-10-23 | 1.7M | 3.0M | 58.4% | 23,505 |
| 2026-10-22 | 4.1M | 6.6M | 62.3% | 40,196 |
| 2026-10-21 | 3.6M | 6.0M | 60.1% | 30,364 |
| 2026-10-20 | 3.9M | 6.2M | 62.1% | 8,966 |
| 2026-10-19 | 5.7M | 9.8M | 58.1% | 10,222 |
| 2026-10-16 | 6.7M | 10.7M | 63.1% | 20,828 |
| 2026-10-15 | 6.1M | 9.7M | 63.2% | 56,966 |
| 2026-10-14 | 10.2M | 15.2M | 67.2% | 57,377 |
| 2026-10-13 | 3.9M | 6.0M | 65.2% | 7,756 |
| 2026-10-12 | 3.5M | 5.6M | 62.3% | 9,259 |
| 2026-10-09 | 5.2M | 10.4M | 49.7% | 54,701 |
| 2026-10-08 | 3.4M | 6.0M | 56.8% | 15,534 |
| 2026-10-07 | 3.5M | 5.7M | 62.7% | 72,968 |
| 2026-10-06 | 4.8M | 8.5M | 57.0% | 28,595 |
| 2026-10-05 | 4.8M | 7.8M | 62.0% | 90,936 |
| 2026-10-02 | 7.9M | 16.5M | 48.0% | 68,238 |
| 2026-10-01 | 3.7M | 6.2M | 59.2% | 28,194 |
| 2026-09-30 | 7.0M | 15.2M | 46.3% | 61,226 |
| 2026-09-29 | 2.3M | 3.8M | 60.5% | 4,471 |
| 2026-09-28 | 2.4M | 4.7M | 51.6% | 9,824 |
| 2026-09-25 | 1.7M | 2.6M | 65.8% | 519 |
| 2026-09-24 | 2.6M | 4.0M | 64.1% | 5,676 |
| 2026-09-23 | 3.9M | 6.9M | 57.0% | 57,387 |
| 2026-09-22 | 3.5M | 10.5M | 33.4% | 33,490 |
| 2026-09-21 | 3.3M | 4.9M | 68.2% | 19,115 |
| 2026-09-18 | 1.5M | 3.7M | 41.7% | 18,982 |
| 2026-09-17 | 3.3M | 8.8M | 37.1% | 55,719 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in IBRX is 3,076 shares, up 7 shares over the last settlement date. Over the last 30 readings it ranged from 1,070 shares (31 August 2026) to 2,098,100 shares (24 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 3,076 | $8.83 | $27K |
| 2026-09-29 | 3,069 | $8.52 | $26K |
| 2026-09-25 | 3,549 | $8.64 | $31K |
| 2026-09-24 | 13,170 | $8.63 | $114K |
| 2026-09-23 | 220,335 | $9.29 | $2.0M |
| 2026-09-22 | 1,883 | $8.45 | $16K |
| 2026-09-21 | 190,544 | $8.48 | $1.6M |
| 2026-09-18 | 96,724 | $8.46 | $818K |
| 2026-09-17 | 13,051 | $7.91 | $103K |
| 2026-09-16 | 9,322 | $8.14 | $76K |
| 2026-09-15 | 43,526 | $8.37 | $364K |
| 2026-09-14 | 3,560 | $7.91 | $28K |
| 2026-09-10 | 2,942 | $8.06 | $24K |
| 2026-09-09 | 2,894 | $8.29 | $24K |
| 2026-09-08 | 1,109 | $8.08 | $9K |
| 2026-09-04 | 3,565 | $8.19 | $29K |
| 2026-09-02 | 7,977 | $7.87 | $63K |
| 2026-09-01 | 150,832 | $7.95 | $1.2M |
| 2026-08-31 | 1,070 | $8.05 | $9K |
| 2026-08-28 | 5,233 | $8.40 | $44K |
| 2026-08-27 | 43,950 | $8.25 | $363K |
| 2026-08-26 | 94,511 | $8.19 | $774K |
| 2026-08-25 | 47,549 | $7.58 | $360K |
| 2026-08-24 | 2,098,100 | $7.79 | $16.3M |
| 2026-08-21 | 21,854 | $7.84 | $171K |
| 2026-08-19 | 3,095 | $7.72 | $24K |
| 2026-08-18 | 17,697 | $7.92 | $140K |
| 2026-08-17 | 2,485 | $7.57 | $19K |
| 2026-08-13 | 6,756 | $7.74 | $52K |
| 2026-08-12 | 2,044 | $7.60 | $16K |
Insider trades
SEC Form 4, newest first. JSONInsiders at IBRX reported 2 open-market sells worth $1.1M in the last 90 days and no open-market buys. Latest filing: Simon Barry J. (Director) on 2026-10-05.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J. | Director | Sell | 25K | $10.75 | $269K | 2.8M |
| 2026-10-02 | Cohen Cheryl | Director | Sell | 81K | $10.50 | $851K | 100K |
| 2026-10-02 | Cohen Cheryl | Director | Exercise or conversion | 56K | $2.98 | $167K | 181K |
| 2026-07-02 | Cohen Cheryl | Director | Sell | 131K | $9.50 | $1.2M | 125K |
| 2026-07-02 | Cohen Cheryl | Director | Exercise or conversion | 56K | $2.98 | $167K | 257K |
| 2026-07-01 | Selecky Christobel | Director | Sell | 159K | $9.02 | $1.4M | 0 |
| 2026-07-01 | Selecky Christobel | Director | Exercise or conversion | 124K | $2.99 | $372K | 159K |
| 2026-07-01 | Selecky Christobel | Director | Exercise or conversion | 35K | $2.98 | $104K | 35K |
| 2026-06-30 | Selecky Christobel | Director | Sell | 1K | $9.00 | $9K | 0 |
| 2026-06-30 | Selecky Christobel | Director | Exercise or conversion | 300 | $2.99 | $897 | 1K |
| 2026-06-30 | Selecky Christobel | Director | Exercise or conversion | 700 | $2.98 | $2K | 700 |
| 2026-06-29 | Selecky Christobel | Director | Sell | 96K | $9.01 | $862K | 0 |
| 2026-06-29 | Selecky Christobel | Director | Exercise or conversion | 30K | $2.84 | $85K | 96K |
| 2026-06-29 | Selecky Christobel | Director | Exercise or conversion | 34K | $2.99 | $100K | 66K |
| 2026-06-29 | Selecky Christobel | Director | Exercise or conversion | 32K | $2.98 | $96K | 32K |
| 2026-06-24 | Simon Barry J. | Director | Sell | 25K | $7.88 | $197K | 2.8M |
| 2026-06-04 | Simon Barry J. | Director | Sell | 23K | $7.18 | $165K | 2.8M |
| 2026-03-31 | CALIFORNIA CAPITAL EQUITY, LLC | TenPercentOwner | Conversion | 4.6M | $5.43 | $25.0M | 251.0M |
| 2026-03-31 | SOON-SHIONG PATRICK | See remarks | Conversion | 4.6M | $5.43 | $25.0M | 251.0M |
| 2026-02-24 | Simon Barry J. | Director | Sell | 75K | $12.01 | $901K | 2.9M |
| 2026-02-23 | Selecky Christobel | Director | Sell | 25K | $10.00 | $250K | 0 |
| 2026-02-23 | Selecky Christobel | Director | Exercise or conversion | 25K | $2.98 | $75K | 25K |
| 2026-02-23 | Simon Barry J. | Director | Sell | 165K | $10.25 | $1.7M | 2.9M |
| 2026-02-22 | CALIFORNIA CAPITAL EQUITY, LLC | TenPercentOwner | Exercise or conversion | 114K | $0.00 | $0 | 29.8M |
| 2026-02-22 | CALIFORNIA CAPITAL EQUITY, LLC | TenPercentOwner | Tax withholding | 58K | $8.70 | $506K | 29.8M |
| 2026-02-22 | Sachs David C. | Chief Financial Officer | Tax withholding | 21K | $8.70 | $180K | 300K |
| 2026-02-22 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 41K | $0.00 | $0 | 321K |
| 2026-02-22 | Simon Barry J. | Director | Tax withholding | 6K | $8.70 | $52K | 3.1M |
| 2026-02-22 | Simon Barry J. | Director | Exercise or conversion | 15K | $0.00 | $0 | 3.1M |
| 2026-02-22 | LAUER REGAN J | Chief Accounting Officer | Tax withholding | 2K | $8.70 | $15K | 116K |
| 2026-02-22 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 4K | $0.00 | $0 | 118K |
| 2026-02-22 | SOON-SHIONG PATRICK | See remarks | Tax withholding | 58K | $8.70 | $506K | 29.8M |
| 2026-02-22 | SOON-SHIONG PATRICK | See remarks | Exercise or conversion | 114K | $0.00 | $0 | 29.8M |
| 2026-02-22 | Adcock Richard | CEO & President | Tax withholding | 78K | $8.70 | $675K | 560K |
| 2026-02-22 | Adcock Richard | CEO & President | Exercise or conversion | 152K | $0.00 | $0 | 638K |
| 2026-02-20 | Simon Barry J. | Director | Sell | 10K | $9.25 | $93K | 3.1M |
| 2026-02-10 | Sachs David C. | Chief Financial Officer | Tax withholding | 43K | $6.93 | $296K | 280K |
| 2026-02-10 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 82K | $0.00 | $0 | 323K |
| 2026-02-10 | LAUER REGAN J | Chief Accounting Officer | Tax withholding | 2K | $6.93 | $16K | 113K |
| 2026-02-10 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 5K | $0.00 | $0 | 116K |
| 2026-02-10 | SOON-SHIONG PATRICK | See remarks | Tax withholding | 119K | $6.93 | $822K | 29.7M |
| 2026-02-10 | SOON-SHIONG PATRICK | See remarks | Exercise or conversion | 274K | $0.00 | $0 | 29.8M |
| 2026-02-10 | Adcock Richard | CEO & President | Tax withholding | 140K | $6.93 | $971K | 485K |
| 2026-02-10 | Adcock Richard | CEO & President | Exercise or conversion | 274K | $0.00 | $0 | 626K |
| 2026-01-20 | Selecky Christobel | Director | Sell | 25K | $7.51 | $188K | 0 |
| 2026-01-20 | Selecky Christobel | Director | Exercise or conversion | 25K | $2.98 | $75K | 25K |
| 2026-01-20 | Simon Barry J. | Director | Sell | 75K | $7.88 | $591K | 3.1M |
| 2026-01-20 | Simon Barry J. | Director | Sell | 77K | $6.54 | $503K | 3.2M |
| 2026-01-16 | Selecky Christobel | Director | Sell | 50K | $5.00 | $250K | 0 |
| 2026-01-16 | Selecky Christobel | Director | Exercise or conversion | 50K | $2.98 | $149K | 50K |
| 2025-12-31 | Sachs David C. | Chief Financial Officer | Tax withholding | 15K | $1.98 | $31K | 241K |
| 2025-12-31 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 30K | $0.00 | $0 | 256K |
| 2025-12-31 | Adcock Richard | CEO & President | Tax withholding | 18K | $1.98 | $35K | 351K |
| 2025-12-31 | Adcock Richard | CEO & President | Exercise or conversion | 34K | $0.00 | $0 | 369K |
| 2025-02-22 | Simon Barry J. | Director | Tax withholding | 5K | $3.42 | $19K | 3.2M |
| 2025-02-22 | Simon Barry J. | Director | Exercise or conversion | 15K | $0.00 | $0 | 3.2M |
| 2025-02-22 | Adcock Richard | CEO & President | Tax withholding | 78K | $3.42 | $267K | 334K |
| 2025-02-22 | Adcock Richard | CEO & President | Exercise or conversion | 152K | $0.00 | $0 | 413K |
| 2025-02-22 | Sachs David C. | Chief Financial Officer | Tax withholding | 16K | $3.42 | $54K | 226K |
| 2025-02-22 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 41K | $0.00 | $0 | 241K |
| 2025-02-22 | SOON-SHIONG PATRICK | See remarks | Tax withholding | 42K | $3.42 | $144K | 29.5M |
| 2025-02-22 | SOON-SHIONG PATRICK | See remarks | Exercise or conversion | 114K | $0.00 | $0 | 29.6M |
| 2025-02-22 | LAUER REGAN J | Chief Accounting Officer | Tax withholding | 2K | $3.42 | $6K | 110K |
| 2025-02-22 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 4K | $0.00 | $0 | 112K |
| 2025-01-22 | Simon Barry J. | Director | Exercise or conversion | 110K | $2.00 | $220K | 3.2M |
| 2024-12-31 | Sachs David C. | Chief Financial Officer | Tax withholding | 15K | $2.56 | $39K | 201K |
| 2024-12-31 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 30K | $0.00 | $0 | 216K |
| 2024-12-31 | Adcock Richard | CEO & President | Tax withholding | 17K | $2.56 | $45K | 260K |
| 2024-12-31 | Adcock Richard | CEO & President | Exercise or conversion | 34K | $0.00 | $0 | 278K |
| 2024-12-15 | LAUER REGAN J | Chief Accounting Officer | Tax withholding | 8K | $2.87 | $22K | 108K |
| 2024-12-15 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 21K | $0.00 | $0 | 115K |
| 2024-12-10 | CALIFORNIA CAPITAL EQUITY, LLC | TenPercentOwner | Conversion | 13.5M | $2.28 | $30.7M | 246.4M |
| 2024-12-10 | CALIFORNIA CAPITAL EQUITY, LLC | TenPercentOwner | Conversion | 103.7M | $1.94 | $201.2M | 232.9M |
| 2024-02-05 | Adcock Richard | CEO & President | Exercise or conversion | 83K | $0.00 | $0 | 286K |
| 2024-02-05 | Adcock Richard | CEO & President | Tax withholding | 43K | $4.04 | $174K | 243K |
| 2024-01-31 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 33K | $0.00 | $0 | 108K |
| 2024-01-31 | LAUER REGAN J | Chief Accounting Officer | Tax withholding | 13K | $3.36 | $45K | 94K |
| 2024-01-31 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 71K | $0.00 | $0 | 213K |
| 2024-01-31 | Sachs David C. | Chief Financial Officer | Tax withholding | 27K | $3.36 | $90K | 186K |
| 2024-01-31 | Simon Barry J. | Director | Tax withholding | 22K | $3.36 | $74K | 3.1M |
| 2024-01-31 | Simon Barry J. | Director | Exercise or conversion | 57K | $0.00 | $0 | 3.1M |
| 2023-12-31 | Adcock Richard | CEO & President | Tax withholding | 17K | $5.02 | $86K | 203K |
| 2023-12-31 | Adcock Richard | CEO & President | Exercise or conversion | 34K | $0.00 | $0 | 220K |
| 2023-12-31 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 30K | $0.00 | $0 | 152K |
| 2023-12-31 | Sachs David C. | Chief Financial Officer | Tax withholding | 11K | $5.02 | $53K | 142K |
| 2023-12-15 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 21K | $0.00 | $0 | 75K |
| 2023-09-11 | Nant Capital, LLC | TenPercentOwner | Other transaction | 129.1M | $1.29 | $166.6M | 129.2M |
| 2023-09-11 | Nant Capital, LLC | TenPercentOwner | Other transaction | 32.6M | $1.29 | $42.1M | 32.6M |
| 2023-09-11 | Nant Capital, LLC | TenPercentOwner | Other transaction | 47.6M | $1.29 | $61.3M | 47.6M |
| 2023-09-01 | Simon Barry J. | Director | Exercise or conversion | 57K | $0.00 | $0 | 3.1M |
| 2023-09-01 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 33K | $0.00 | $0 | 54K |
| 2023-09-01 | Sachs David C. | Chief Financial Officer | Exercise or conversion | 71K | $0.00 | $0 | 122K |
| 2023-06-15 | LAUER REGAN J | Chief Accounting Officer | Exercise or conversion | 21K | $0.00 | $0 | 21K |
| 2023-06-05 | BLASZYK MICHAEL D | Director | Buy | 485 | $2.75 | $1K | 72K |
| 2023-06-05 | BLASZYK MICHAEL D | Director | Buy | 23K | $2.72 | $64K | 23K |
| 2023-06-05 | BLASZYK MICHAEL D | Director | Buy | 48K | $2.77 | $133K | 71K |
| 2023-06-02 | Brennan John Owen | Director | Buy | 10K | $2.90 | $29K | 25K |
| 2023-06-02 | Brennan John Owen | Director | Buy | 10K | $2.80 | $28K | 15K |
| 2023-06-02 | Brennan John Owen | Director | Buy | 5K | $2.74 | $14K | 5K |
| 2023-06-01 | Clark Wesley | Director | Buy | 7K | $2.91 | $20K | 8K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON11 Form 144 notices on file for IBRX worth $21.3M at the prices reported; 2 in the last 90 days worth $8.4M. Latest: Simon Barry J. filed on 2026-10-05 to sell 560,000 shares ($7.7M) from 2026-10-05.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J.Officer, Director | 560K | $7.7M | 0.053% | 2026-10-05 | THE CHARLES SCHWAB CORPORATION |
| 2026-10-02 | CHERYL COHENDirector | 81K | $752K | 0.008% | 2026-10-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-02 | CHERYL L COHENOfficer | 131K | $1.2M | 0.013% | 2026-07-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | CHRISTOBEL SELECKYDirector | 159K | $1.4M | 0.015% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-30 | CHRISTOBEL SELECKYDirector | 1K | $9K | 0.000% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | CHRISTOBEL SELECKYDirector | 96K | $834K | 0.009% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | Simon Barry J.Officer, Director | 268K | $2.9M | 0.026% | 2026-06-04 | THE CHARLES SCHWAB CORPORATION |
| 2026-02-23 | CHRISTOBEL SELECKYDirector | 25K | $218K | 0.003% | 2026-02-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-20 | CHRISTOBEL SELECKYDirector | 25K | $138K | 0.003% | 2026-01-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-20 | Simon Barry J.Officer, Director | 572K | $5.9M | 0.058% | 2026-01-20 | THE CHARLES SCHWAB CORPORATION |
| 2026-01-16 | CHRISTOBEL SELECKYDirector | 50K | $198K | 0.005% | 2026-01-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of IBRX in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Patrick Soon-Shiong at 64.8% of the class (745,518,285 shares), filed 2026-08-06 for an event on 2026-07-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-06 | 13D/Ano. 13 | Patrick Soon-Shiongindividual | 745.5M | 64.8% | 2026-07-31 |
| 2026-08-06 | 13D/Ano. 13 | Nant Capital, LLCother entity | 339.5M | 29.6% | 2026-07-31 |
| 2026-08-06 | 13D/Ano. 13 | Cambridge Equities, LPpartnership | 261.7M | 24.7% | 2026-07-31 |
| 2026-08-06 | 13D/Ano. 13 | MP 13 Ventures, LLCother entity | 261.7M | 24.7% | 2026-07-31 |
| 2026-08-06 | 13D/Ano. 13 | California Capital Equity, LLCother entity | 106.5M | 10.0% | 2026-07-31 |
| 2026-08-06 | 13D/Ano. 13 | NantWorks, LLCother entity | 98.5M | 9.3% | 2026-07-31 |
| 2025-11-10 | 13D/Ano. 11 | NantMobile, LLCother entity | 47.6M | 4.8% | 2025-11-10 |
13F holders
Tracked managers holding IBRX at their latest 13F. JSON6 of the 30 tracked managers held IBRX at their latest 13F, $259.3M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $101.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 11.6M | $101.1M | 0.05% | -1.0M |
| Two Sigma Investments | 2026-06-30 | 11.1M | $97.2M | 0.07% | +6.7M |
| Millennium Management | 2026-06-30 | 5.6M | $48.9M | 0.02% | +4.2M |
| Renaissance Technologies | 2026-06-30 | 1.0M | $9.0M | 0.01% | new |
| AQR Capital Management | 2026-06-30 | 223K | $2.0M | 0.00% | +156K |
| Citadel Advisors | 2026-06-30 | 136K | $1.2M | 0.00% | -170K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) ImmunityBio reported revenue of $51.2M, up 93.9% from the same quarter a year earlier, and net loss of $230.4M (-0.22 diluted EPS). In FY 2025 it generated -$304.9M of operating cash flow.
- Cash
- $75.7M
- Equity
- -$1.05B
- Total assets
- $628.5M
- Shares outstanding
- 1,059,836,273
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $51.2M | -$230.4M | -449.6% | -0.22 |
| Q1 FY 2026 | 2026-03-31 | $44.2M | -$632.8M | -1431.4% | -0.62 |
| Q4 FY 2025derived | 2025-12-31 | $38.3M | -$61.9M | -161.8% | n/a |
| Q3 FY 2025 | 2025-09-30 | $32.1M | -$67.3M | -209.8% | -0.07 |
| Q2 FY 2025 | 2025-06-30 | $26.4M | -$92.6M | -350.3% | -0.10 |
| Q1 FY 2025 | 2025-03-31 | $16.5M | -$129.6M | -784.9% | -0.15 |
| Q4 FY 2024derived | 2024-12-31 | $7.6M | -$59.2M | -783.4% | n/a |
| Q3 FY 2024 | 2024-09-30 | $6.1M | -$85.7M | -1404.0% | -0.14 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $113.3M | -$351.4M | -$304.9M | $3.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $14.7M | -$413.6M | -$391.2M | $6.9M | n/a | n/a |
| FY 2023 | 2023-12-31 | $622K | -$583.2M | -$366.8M | $30.6M | n/a | n/a |
| FY 2022 | 2022-12-31 | $240K | -$416.6M | -$337.5M | $78.2M | n/a | n/a |
| FY 2021 | 2021-12-31 | $934K | -$346.8M | -$274.4M | $33.6M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
ImmunityBio in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows ImmunityBio (IBRX), SEC CIK 1326110, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-05.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-05.JSON and CSV
- Company record
- EDGAR filing index for CIK 1326110Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of IBRX is sold short?
122,945,839 shares were held short at the 2026-10-15 settlement, 7.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is IBRX's daily short volume?
On 2026-10-28, 2,134,578 of the 3,542,307 IBRX shares reported to FINRA were sold short, 60.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does IBRX have fails to deliver?
The SEC's latest file shows 3,076 IBRX shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are IBRX insiders buying or selling?
Insiders at IBRX reported 2 open-market sells worth $1.1M in the last 90 days and no open-market buys. Latest filing: Simon Barry J. (Director) on 2026-10-05.
Have IBRX insiders filed to sell?
11 Form 144 notices on file for IBRX worth $21.3M at the prices reported; 2 in the last 90 days worth $8.4M. Latest: Simon Barry J. filed on 2026-10-05 to sell 560,000 shares ($7.7M) from 2026-10-05.
Who owns 5% or more of IBRX?
6 holders report 5% or more of IBRX in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Patrick Soon-Shiong at 64.8% of the class (745,518,285 shares), filed 2026-08-06 for an event on 2026-07-31.
What did IBRX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) ImmunityBio reported revenue of $51.2M, up 93.9% from the same quarter a year earlier, and net loss of $230.4M (-0.22 diluted EPS). In FY 2025 it generated -$304.9M of operating cash flow.
Which tracked 13F managers own IBRX?
6 of the 30 tracked 13F managers held IBRX shares at their latest filing, $259.3M in all. The largest: D. E. Shaw & Co. (11.6M shares, $101.1M), Two Sigma Investments (11.1M shares, $97.2M), Izzy Englander's Millennium Management (5.6M shares, $48.9M), Renaissance Technologies (1.0M shares, $9.0M), Cliff Asness's AQR Capital Management (223K shares, $2.0M), Ken Griffin's Citadel Advisors (136K shares, $1.2M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.